Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study.
Achiron A, Mandel M, Dreyer-Alster S, Harari G, Dolev M, Menascu S, Magalashvili D, Flechter S, Givon U, Guber D, Sonis P, Zilkha-Falb R, Gurevich M. Achiron A, et al. Among authors: flechter s. J Neuroimmunol. 2021 Dec 15;361:577746. doi: 10.1016/j.jneuroim.2021.577746. Epub 2021 Oct 9. J Neuroimmunol. 2021. PMID: 34655991 Free PMC article.
Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod.
Achiron A, Mandel M, Gurevich M, Dreyer-Alster S, Magalashvili D, Sonis P, Dolev M, Menascu S, Harari G, Flechter S, Falb R. Achiron A, et al. Among authors: flechter s. J Neurol. 2022 May;269(5):2286-2292. doi: 10.1007/s00415-022-11030-0. Epub 2022 Mar 2. J Neurol. 2022. PMID: 35235002 Free PMC article. Clinical Trial.
COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021.
Achiron A, Dolev M, Menascu S, Zohar DN, Dreyer-Alster S, Miron S, Shirbint E, Magalashvili D, Flechter S, Givon U, Guber D, Stern Y, Polliack M, Falb R, Gurevich M. Achiron A, et al. Among authors: flechter s. Mult Scler. 2021 May;27(6):864-870. doi: 10.1177/13524585211003476. Epub 2021 Apr 15. Mult Scler. 2021. PMID: 33856242 Free PMC article.
Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.
Achiron A, Mandel M, Dreyer-Alster S, Harari G, Magalashvili D, Sonis P, Dolev M, Menascu S, Flechter S, Falb R, Gurevich M. Achiron A, et al. Among authors: flechter s. Ther Adv Neurol Disord. 2021 Apr 22;14:17562864211012835. doi: 10.1177/17562864211012835. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 34035836 Free PMC article.
SARS-CoV-2 memory B and T cell profiles in mild COVID-19 convalescent patients.
Gurevich M, Zilkha-Falb R, Sonis P, Magalashvili D, Menascu S, Flechter S, Dolev M, Mandel M, Achiron A. Gurevich M, et al. Among authors: flechter s. Int J Infect Dis. 2022 Feb;115:208-214. doi: 10.1016/j.ijid.2021.12.309. Epub 2021 Dec 8. Int J Infect Dis. 2022. PMID: 34896265 Free PMC article.
COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose.
Dreyer-Alster S, Menascu S, Mandel M, Shirbint E, Magalashvili D, Dolev M, Flechter S, Givon U, Guber D, Stern Y, Miron S, Polliack M, Falb R, Sonis P, Gurevich M, Achiron A. Dreyer-Alster S, et al. Among authors: flechter s. J Neurol Sci. 2022 Mar 15;434:120155. doi: 10.1016/j.jns.2022.120155. Epub 2022 Jan 21. J Neurol Sci. 2022. PMID: 35091386 Free PMC article.
Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.
Achiron A, Mandel M, Dreyer-Alster S, Harari G, Magalashvili D, Sonis P, Dolev M, Menascu S, Flechter S, Falb R, Gurevich M. Achiron A, et al. Among authors: flechter s. Ther Adv Neurol Disord. 2021 May 29;14:17562864211020082. doi: 10.1177/17562864211020082. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 34104221 Free PMC article. No abstract available.
63 results